A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-68179280 in Healthy Participants
Latest Information Update: 26 Jul 2023
At a glance
- Drugs JNJ-68179280 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 21 Jul 2023 Status changed from recruiting to completed.
- 14 Mar 2023 Planned End Date changed from 19 Jun 2023 to 13 Jun 2023.
- 14 Mar 2023 Planned primary completion date changed from 31 Jan 2023 to 13 Jun 2023.